查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1411376

反義和 RNAi 治療市場：按技術、應用和給藥途徑給藥- 2024-2030 年全球預測

Antisense & RNAi Therapeutics Market by Technology (Antisense RNA, RNA Interference), Application (Cardiovascular Diseases (CVDs), Genetic Disorders, Infectious Diseases), Route of Administration - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年反義和RNAi治療市場規模為45.1億美元，2024年達49.3億美元，預計2030年將達到84.3億美元，複合年成長率為9.34%。

反義和 RNAi 療法的全球市場

主要市場統計
基準年[2023] 45.1億美元
預測年份 [2024] 49.3億美元
預測年份 [2030] 84.3億美元
複合年成長率（%） 9.34%
反義和RNAi治療市場-IMG1

FPNV定位矩陣

FPNV 定位矩陣對於評估反義和 RNAi 治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對反義和 RNAi 治療市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-反義和RNAi治療市場的市場規模和預測是多少？

2-在反義和 RNAi 治療市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3-反義和RNAi治療市場的技術趨勢和法律規範是什麼？

4-反義和RNAi治療市場主要供應商的市場佔有率是多少？

5-進入反義和RNAi治療市場的適當型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界老年人口增加和慢性病盛行率
      • 對新的有效治療方法的需求不斷成長
      • 增加反義和 RNAi治療方法的研發活動
    • 抑制因素
      • 反義RNAi療法的製造成本很高
    • 機會
      • 反義RNAi治療的臨床進展
      • 反義 RNAi 治療發現和開發的重大投資
    • 任務
      • 對反義 RNAi 療法療效的擔憂
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章反義與 RNAi 治療市場：依技術分類

  • 反義RNA
  • RNA干擾
    • miRNA
    • siRNA

第7章反義與 RNAi 治療市場：依應用分類

  • 心血管疾病（CVD）
  • 遺傳疾病
  • 感染疾病
  • 神經退化性疾病
  • 腫瘤學
  • 腎臟疾病
  • 呼吸系統疾病

第 8 章反義與 RNAi 治療市場：依給藥途徑

  • 皮內注射
  • 腹腔注射
  • 靜脈注射
  • 肺部輸送
  • 話題分佈

第9章美洲反義和RNAi治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太反義和RNAi治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的反義和RNAi治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：按主要企業分類
  • 主要企業競爭情境分析

第13章競爭產品組合

  • 主要公司簡介
    • Alnylam Pharmaceuticals, Inc.
    • Amarna Therapeutics BV
    • Arbutus Biopharma Corporation
    • Arrowhead Pharmaceuticals, Inc.
    • AstraZeneca plc
    • Axolabs GmbH
    • Benitec Biopharma Limited
    • BioNTech SE
    • Carisma Therapeutics Inc.
    • Dicerna Pharmaceuticals, Inc.
    • Evox Therapeutics Ltd
    • Exicure, Inc.
    • GenScript Biotech Corporation
    • InteRNA Technologies BV
    • Ionis Pharmaceuticals, Inc.
    • miRagen Therapeutics, Inc.
    • Regenxbio Inc.
    • RXi Pharmaceuticals Corporation
    • Sanofi SA
    • Silence Therapeutics plc
    • Sirnaomics, Inc.
    • Wave Life Sciences Ltd
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-8E22B61932D4

[195 Pages Report] The Antisense & RNAi Therapeutics Market size was estimated at USD 4.51 billion in 2023 and expected to reach USD 4.93 billion in 2024, at a CAGR 9.34% to reach USD 8.43 billion by 2030.

Global Antisense & RNAi Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 4.51 billion
Estimated Year [2024] USD 4.93 billion
Forecast Year [2030] USD 8.43 billion
CAGR (%) 9.34%
Antisense & RNAi Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antisense & RNAi Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antisense & RNAi Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antisense & RNAi Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Amarna Therapeutics BV, Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., AstraZeneca plc, Axolabs GmbH, Benitec Biopharma Limited, BioNTech SE, Carisma Therapeutics Inc., Dicerna Pharmaceuticals, Inc., Evox Therapeutics Ltd, Exicure, Inc., GenScript Biotech Corporation, InteRNA Technologies BV, Ionis Pharmaceuticals, Inc., miRagen Therapeutics, Inc., Regenxbio Inc., RXi Pharmaceuticals Corporation, Sanofi S.A., Silence Therapeutics plc, Sirnaomics, Inc., and Wave Life Sciences Ltd.

Market Segmentation & Coverage

This research report categorizes the Antisense & RNAi Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Antisense RNA
    • RNA Interference
      • miRNA
      • siRNA
  • Application
    • Cardiovascular Diseases (CVDs)
    • Genetic Disorders
    • Infectious Diseases
    • Neurodegenerative Disorders
    • Oncology
    • Renal Diseases
    • Respiratory Disorders
  • Route of Administration
    • Intra-dermal Injections
    • Intraperitoneal Injections
    • Intravenous Injections
    • Pulmonary Delivery
    • Topical Delivery
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antisense & RNAi Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antisense & RNAi Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Antisense & RNAi Therapeutics Market?

4. What is the market share of the leading vendors in the Antisense & RNAi Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Antisense & RNAi Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antisense & RNAi Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in geriatric populations and prevalence of chronic diseases worldwide
      • 5.1.1.2. Growing need for effective and novel therapeutics
      • 5.1.1.3. Increase in R&D activities on antisense and RNAi-based therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of manufacturing antisense-RNAi-therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Clinical advancements in antisense-RNAi-therapeutics
      • 5.1.3.2. Significant investments in the discovery and development of antisense-RNAi-therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with the efficacy of antisense-RNAi-therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antisense & RNAi Therapeutics Market, by Technology

  • 6.1. Introduction
  • 6.2. Antisense RNA
  • 6.3. RNA Interference
    • 6.4.1. miRNA
    • 6.4.2. siRNA

7. Antisense & RNAi Therapeutics Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular Diseases (CVDs)
  • 7.3. Genetic Disorders
  • 7.4. Infectious Diseases
  • 7.5. Neurodegenerative Disorders
  • 7.6. Oncology
  • 7.7. Renal Diseases
  • 7.8. Respiratory Disorders

8. Antisense & RNAi Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intra-dermal Injections
  • 8.3. Intraperitoneal Injections
  • 8.4. Intravenous Injections
  • 8.5. Pulmonary Delivery
  • 8.6. Topical Delivery

9. Americas Antisense & RNAi Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antisense & RNAi Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antisense & RNAi Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Alnylam Pharmaceuticals, Inc.
    • 13.1.2. Amarna Therapeutics BV
    • 13.1.3. Arbutus Biopharma Corporation
    • 13.1.4. Arrowhead Pharmaceuticals, Inc.
    • 13.1.5. AstraZeneca plc
    • 13.1.6. Axolabs GmbH
    • 13.1.7. Benitec Biopharma Limited
    • 13.1.8. BioNTech SE
    • 13.1.9. Carisma Therapeutics Inc.
    • 13.1.10. Dicerna Pharmaceuticals, Inc.
    • 13.1.11. Evox Therapeutics Ltd
    • 13.1.12. Exicure, Inc.
    • 13.1.13. GenScript Biotech Corporation
    • 13.1.14. InteRNA Technologies BV
    • 13.1.15. Ionis Pharmaceuticals, Inc.
    • 13.1.16. miRagen Therapeutics, Inc.
    • 13.1.17. Regenxbio Inc.
    • 13.1.18. RXi Pharmaceuticals Corporation
    • 13.1.19. Sanofi S.A.
    • 13.1.20. Silence Therapeutics plc
    • 13.1.21. Sirnaomics, Inc.
    • 13.1.22. Wave Life Sciences Ltd
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANTISENSE & RNAI THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTISENSE & RNAI THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTISENSE & RNAI THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE RNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 9. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MIRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SIRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES (CVDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RENAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRA-DERMAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAPERITONEAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PULMONARY DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 194. ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. ANTISENSE & RNAI THERAPEUTICS MARKET LICENSE & PRICING